This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koslowski, M. Articles by Türeci, O. Search for Related Content PubMed PubMed Citation Articles by Koslowski, M. Articles by Türeci, O.

A Placenta-Specific Gene Ectopically Activated in Many Human Cancers Is Essentially Involved in Malignant Cell Processes

¹ Department of Internal Medicine III, Division of Experimental and Translational Oncology, Johannes Gutenberg University and ² Ganymed Pharmaceuticals AG, Mainz, Germany and ³ Institute of Pathology, Bamberg Hospital, Bamberg, Germany

Requests for reprints: Özlem Türeci, Ganymed Pharmaceuticals AG, Freiligrathstr. 12, 55131 Mainz, Germany. Phone: 49-6131-1440100; Fax: 49-6131-1440111; E-mail: oe.tuereci{at}ganymed-pharmaceuticals.com.

The identification and functional characterization of tumor-specific genes is a prerequisite for the development of targeted cancer therapies. Using an integrated data mining and experimental validation approach for the discovery of new targets for antibody therapy of cancer, we identified PLAC1. PLAC1 is a placenta-specific gene with no detectable expression in any other normal human tissue. However, it is frequently aberrantly activated and highly expressed in a variety of tumor types, in particular breast cancer. RNAi-mediated silencing of PLAC1 in MCF-7 and BT-549 breast cancer cells profoundly impairs motility, migration, and invasion and induces a G₁-S cell cycle block with nearly complete abrogation of proliferation. Knockdown of PLAC1 is associated with decreased expression of cyclin D1 and reduced phosphorylation of AKT kinase. Moreover, PLAC1 is localized on the surface of cancer cells and is accessible for antibodies which antagonize biological functions of this molecule. These features, in summary, make PLAC1 an attractive candidate for targeted immunotherapeutic approaches. [Cancer Res 2007;67(19):9528–34]

This article has been cited by other articles:

				M. Koslowski, O. Tureci, S. Biesterfeld, G. Seitz, C. Huber, and U. Sahin Selective Activation of Trophoblast-specific PLAC1 in Breast Cancer by CCAAT/Enhancer-binding Protein {beta} (C/EBP{beta}) Isoform 2 J. Biol. Chem., October 16, 2009; 284(42): 28607 - 28615. [Abstract] [Full Text] [PDF]

				B. Novakovic, V. Rakyan, H.K. Ng, U. Manuelpillai, C. Dewi, N.C. Wong, R. Morley, T. Down, S. Beck, J.M. Craig, et al. Specific tumour-associated methylation in normal human term placenta and first-trimester cytotrophoblasts Mol. Hum. Reprod., September 1, 2008; 14(9): 547 - 554. [Abstract] [Full Text] [PDF]